A. Babiak, J. Hetzel, F. Godde, H. Konig, M. Pietsch et al., Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC ??? a phase II trial, British Journal of Cancer, vol.53, issue.7, pp.1052-1058, 2007.
DOI : 10.1158/1078-0432.CCR-05-1048

M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard et al., Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer, Annals of Pharmacotherapy, vol.42, issue.11, pp.1640-52, 2008.
DOI : 10.1345/aph.1L200

L. Billingham, S. Bathers, A. Burton, S. Bryan, and M. Cullen, Patterns, costs and cost-effectiveness of care in a trial of chemotherapy for advanced non-small cell lung cancer, Lung Cancer, vol.37, issue.2, pp.219-244, 2002.
DOI : 10.1016/S0169-5002(02)00042-9

L. Bordeleau, Pharmacoeconomics of Systemic Therapies for Lung Cancer, Treatments in Respiratory Medicine, vol.4, issue.32, pp.129-170, 2006.
DOI : 10.2165/00151829-200605020-00006

. Mitomycin, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life, J Clin Oncol, vol.17, issue.10, pp.3188-94, 1999.

K. Dedes, T. Szucs, S. Bodis, M. Joerger, A. Lowy et al., Management and Costs of Treating Lung Cancer Patients in a University Hospital, PharmacoEconomics, vol.79, issue.5
DOI : 10.2165/00019053-200422070-00003

G. Colucci, Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Grupo oncologica Italia meridionale, Lung Cancer, vol.38, issue.1, pp.79-84, 2002.

K. Glover, R. Perez-soler, and V. Papadimitradopoulou, A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer, Seminars in Oncology, vol.31, issue.1 1, pp.83-92, 2004.
DOI : 10.1053/j.seminoncol.2003.12.019

H. Gravelle and M. Backhouse, International cross-section analysis of the determination of mortality, Social Science & Medicine, vol.25, issue.5, pp.427-468, 1987.
DOI : 10.1016/0277-9536(87)90167-5

W. Greene, Econometric Analysis 5th edition, 2003.

C. Gridelli, M. Aapro, and A. Ardizzoni, Treatment of Advanced Non???Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel, Journal of Clinical Oncology, vol.23, issue.13, pp.3125-3162, 2005.
DOI : 10.1200/JCO.2005.00.224

B. Daniele, D. Galetta, S. Barbera, F. Rosetti, A. Rossi et al., Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol, pp.500-512, 2007.

T. Hensing, F. Detterbeck, and M. Socinski, The role of induction therapy in the management of resectable non-small cell lung cancer, Cancer Control, vol.7, issue.1, pp.45-55, 2000.

M. Lees, M. Aristides, N. Maniadakis, J. Mckendrick, N. Botwood et al., Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer, PharmacoEconomics, vol.346, issue.5, pp.325-362, 2002.
DOI : 10.2165/00019053-200220050-00004

F. Lichtenberg, The expanding pharmaceutical arsenal in the war on cancer, 2004.
DOI : 10.3386/w10328

E. Nolte, M. Kee, and M. , Does care save lives? London: The Nuffield Trust, 2004.

S. Burdett, Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials

S. Martin, N. Rice, and P. Smith, Does health care spending improve health outcomes? Evidence from English programme budgeting data, Journal of Health Economics, vol.27, issue.4, pp.826-868, 2008.
DOI : 10.1016/j.jhealeco.2007.12.002
URL : http://spiral.imperial.ac.uk/bitstream/10044/1/15637/2/Journal%20of%20Health%20Economics_27_4_2008.pdf

M. Perry, L. Kohman, J. Bonner, L. Gu, X. Wang et al., A Phase III Study of Surgical Resection and Paclitaxel/Carboplatin Chemotherapy with or Without Adjuvant Radiation Therapy for Resected Stage III Non???Small-Cell Lung Cancer: Cancer and Leukemia Group B 9734, Clinical Lung Cancer, vol.8, issue.4, pp.268-72, 2007.
DOI : 10.3816/CLC.2007.n.005

J. Pujol, J. Breton, R. Gervais, P. Rebattu, A. Depierre et al., Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin, Annals of Oncology, vol.16, issue.4, pp.602-612, 2005.
DOI : 10.1093/annonc/mdi126

C. Rubio-terrès, J. Tisaire, S. Kobina, and A. Moyano, Cost-minimisation analysis of three regimens of chemotherapy (docetaxel???cisplatin, paclitaxel???cisplatin, paclitaxel???carboplatin) for advanced non-small-cell lung cancer, Lung Cancer, vol.35, issue.1, pp.81-90, 2002.
DOI : 10.1016/S0169-5002(01)00280-X

S. Leger and S. , The anomaly that finally went away?, Journal of Epidemiology & Community Health, vol.55, issue.2, p.79, 2001.
DOI : 10.1136/jech.55.2.79

L. Sequist and T. Lynch, Aggressive Treatment for the Fit Elderly With Non???Small-Cell Lung Cancer? Yes!, Journal of Clinical Oncology, vol.21, issue.17, pp.3186-88, 2003.
DOI : 10.1200/JCO.2003.04.002

M. Socinski, M. Baggstrom, and T. Hensing, Duration of therapy in advance metastatic non small cell cancer, Clinical advances in Hematology and Oncology, vol.1, issue.1, pp.33-38, 2003.

S. Thongprasert, P. Sanguanmitra, W. Juthapan, and J. Clinch, Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy, Lung Cancer, vol.24, issue.1, pp.17-24, 1999.
DOI : 10.1016/S0169-5002(99)00017-3

C. Tigue, K. Fitzner, M. Alkhatib, E. Schmid, and C. Bennett, The value of innovation: the economics of targeted drugs for cancer, Targeted Oncology, vol.19, issue.2, pp.113-119, 2007.
DOI : 10.1007/s11523-007-0043-8

W. Van-den-hout, G. Kramer, E. Noordijk, and J. Leer, Cost-Utility Analysis of Short- Versus Long-Course Palliative Radiotherapy in Patients With Non-Small-Cell Lung Cancer, JNCI Journal of the National Cancer Institute, vol.98, issue.24, pp.1786-94, 2006.
DOI : 10.1093/jnci/djj496

A. Vergnenegre, C. Combescure, P. Fournel, S. Bayle, C. Gimenez et al., Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01), Annals of Oncology, vol.17, issue.8, pp.1269-74, 2006.
DOI : 10.1093/annonc/mdl100

F. Young, An explanation of the persistent doctor-mortality association, Journal of Epidemiology & Community Health, vol.55, issue.2, pp.80-84, 2001.
DOI : 10.1136/jech.55.2.80